Med BioGene - Improving Diagnosis and Treatment

Featured News

June 16, 2008

Med BioGene Expands Lymphoma Collaboration; Becomes Founding Corporate Collaborator of Translational Working Group in Hematologic Malignancies

May 29, 2008

Med BioGene Appoints Diagnostics Industry Veteran Dr. Heiner Dreismann to Board of Directors

April 23, 2008

Med BioGene and University Health Network Collaborate to Commercialize Critical Lung Cancer Prognostic Test

Home	Improving Diagnosis and Treatment

Improving Diagnosis and Treatment

MBI is developing genomic-based clinical laboratory diagnostic and screening tests by identifying the genes, known as "biomarkers," that indicate the presence of disease. The development of these biomarkers is the first step towards personalized medicine and will replace the conventional "one drug fits all" approach to disease management.

Expected Benefits

Improved Diagnostics	MBI’s tests are expected to provide more accurate, objective and quicker diagnosis, allowing healthcare providers to deliver more appropriate and timely care to patients.
Personalized Treatment	MBI's tests outline a patient’s genetic profile and may assist doctors in tailoring treatment decisions to the needs of each patient, thus making treatment more effective and reducing healthcare costs by minimizing the treatment of non-responders.
Therapeutic Development	Pharmaceutical companies can prioritze MBI's genomic biomarkers for use as potential therapeutic targets and to validate the effectiveness of specific therapeutics.

E-MAIL ALERTS

Subscribe to our e-mail news alerts

Quick Facts

Download our facts sheet